Armagen, Inc.
Records under this name other than the patents Armagen, Inc. holds now: patents now held by others, patents whose terms have ended, and its applications, pending or abandoned. None of them is counted in the 5 patents it holds.
| Patent | Title | Status | Expires | Confidence |
|---|---|---|---|---|
| US 7,741,446 | Fusion Antibodies That Cross the Blood-Brain Barrier in Both Directions now held by JCR Pharmaceuticals Co., Ltd. In force · High confidence | In force | High confidence | |
| US 9,567,400 | Methods and Compositions for Increasing Alpha-L-Iduronidase Activity in the CNS now held by JCR Pharmaceuticals Co., Ltd. In force · High confidence | In force | High confidence | |
| US 10,202,467 | Methods and Compositions for Increasing Alpha-L-Iduronidase Activity in the CNS now held by JCR Pharmaceuticals Co., Ltd. In force · Medium confidence | In force | Medium confidence | |
| US 8,834,874 | Methods and Compositions for Increasing Iduronate 2-Sulfatase Activity in the CNS now held by JCR Pharmaceuticals Co., Ltd. In force · High confidence | In force | High confidence | |
| US 10,011,651 | Methods and Compositions for Increasing Iduronate 2-Sulfatase Activity in the CNS now held by JCR Pharmaceuticals Co., Ltd. In force · High confidence | In force | High confidence | |
| US 8,486,399 | Methods and Compositions for Increasing Arylsulfatase A Activity in the CNS now held by JCR Pharmaceuticals Co., Ltd. In force · High confidence | In force | High confidence | |
| US 8,920,801 | Methods and Compositions for Increasing Arylsulfatase a Activity in the CNS now held by JCR Pharmaceuticals Co., Ltd. In force · High confidence | In force | High confidence | |
| US 10,538,589 | Methods and Compositions for Increasing N-Acetylglucosaminidase Activity in the CNS now held by JCR Pharmaceuticals Co., Ltd. In force · High confidence | In force | High confidence | |
| US 8,759,297 | Genetically Encoded Multifunctional Compositions Bidirectionally Transported Between Peripheral Blood and the CNS now held by JCR Pharmaceuticals Co., Ltd. Lapsed on the fee record Ended Jun 24, 2026 · High confidence | Lapsed on the fee record | Ended Jun 24, 2026 | High confidence |
| US 8,753,610 | Methods for Diagnosing CNS Disorders with Fusion Antibodies That Cross the Blood-Brain Barrier in Both Directions now held by JCR Pharmaceuticals Co., Ltd. Lapsed on the fee record Ended Jun 17, 2026 · High confidence | Lapsed on the fee record | Ended Jun 17, 2026 | High confidence |